| Business Summary | | Polydex
Pharmaceuticals
Limited,
through
its
subsidiaries,
manufactures
and
sells
Dextran
and
several
of
its
derivatives,
including
Iron
Dextran
and
Dextran
Sulphate,
veterinary
pharmaceutical
products
and
other
specialty
chemicals
and
cosmetic
raw
materials,
with
some
related
research
and
development.
The
Company
is
investigating
the
potential
human
applications
of
some
of
its
products.
Iron
Dextran
is
a
derivative
of
Dextran,
produced
by
complexing
Iron
with
Dextran.
Iron
extran
is
injected
into
most
pigs
at
birth
as
a
treatment
for
anemia.
Dextran
Sulphate
is
a
specialty
chemical
that
finds
use
in
research
applications
of
the
pharmaceutical
industry
and
other
centers
of
chemical
research.
The
Company
also
manufactures
sterile
injectable
products,
tablets
and
boluses,
internal
and
external
solutions,
ointments
and
powders. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Polydex
Pharmaceuticals,
through
the
Company
's
subsidiaries,
is
engaged
in
the
manufacturing
and
sale
of
veterinary
pharmaceutical
products
and
specialty
chemicals.
For
the
three
months
ended
4/30/01,
revenues
fell
10%
to
$3.1
million.
Net
loss
totaled
$65
thousand,
vs.
an
income
of
$80
thousand.
Revenues
reflect
decreased
sales
in
the
injectable
product
line.
Net
loss
also
reflects
higher
average
costs
for
fixed
manufacturing
overheads
and
increased
R&D
expenses. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY2000 Pay | |
| George Usher, 42 Chairman,
Pres and CEO | $135K | Thomas Usher, 86 Vice
Chairman | 220K | Sharon Wardlaw, 48 CFO,
Sec. and Treasurer | -- | Dollar amounts are as of 31-Jan-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|